R.I. GABIDULLINA¹, E.I. GALIMYANOVA¹, V.I. EREMKINA¹, A.M. SHARAPOVA²

 ¹Kazan State Medical University, Kazan

²Volga region Center of Oncodiagnostics, Kazan

 Contact details:

Gabidullina R.I. — MD, Professor of the Department of Obstetrics and Gynecology named after V.S. Gruzdev

Address: 49 Butlerov St., Russian Federation, Kazan, 420012, tel.: +7-917-28-99-310, e-mail: [email protected]

The purpose — to evaluate the effect of combined oral contraceptive containing 17β-estradiol on sexuality, severity of depression and quality of life in women of reproductive age.

Material and methods. The study involved 53 women in need of contraception aged 18 to 50 years. For the contraceptive purpose women used COC containing 1,5 mg of 17 β -estradiol (E2) and 2,5 mg of nomegestrol acetate (NOMAC) (E2/NOMAC). The questionnaires used in the study are: Female Sexuality Function Index (FSFI-6), Beck Depression Inventory, SF-36 — for evaluating Health-Related Quality of Life. The survey was conducted before and after six months of E2/NOMAC intake; the correlations between the studied parameters and the level of sex hormones in patient’s blood sample were determined.

Results. The intake of E2/NOMAC for 6 months did not have negative effect on Female Sexuality Function Index. At the same time, a statistically significant improvement up to 5 points was revealed in such parameters as sexual satisfaction (p = 0,03) and lubrication (p < 0,001). There was a significant decrease in the frequency and severity of depression measured by the Beck Depression Inventory. The Short Form-36 Health Survey revealed a tendency to improve the physical and mental health components of the quality of life (p> 0,05). The change in total testosterone level had a moderate negative relationship with the change in Female Sexuality Function Index (r = — 0,32; p = 0,02).

Conclusion. The intake of combined oral contraceptive containing 17β-estradiol for 6 months was associated with no adverse impact on female sexuality and quality of life in women of reproductive age, and reduced the levels of frequency and severity of depression.

Key words: combined oral contraceptives, sexual function, depression, quality of life.

REFERENCES

1. Burkman R., Bell C., Serfaty D. The evolution of combined oral contraception: improving the risk-to-benefit ratio. Contraception, 2011, vol. 84, pp. 19–34.
2. Mansour D., Verhoeven C., Sommer W. Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur. J. Contracept. Reprod. Health Care, 2011, vol. 16 (6), pp. 430–443.
3. Ågren U.M., Anttila M., Mäenpää-Liukko K. et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. Eur. J. Contracept. Reprod. Health Care, 2011, vol. 16 (6), pp. 444-457.
4. Prilepskaya V.N., Abakarova P.R., Yarotskaya E.L. Modern contraception and woman’s quality of life. Doktor.Ru, 2017, no. 3 (132), S. 37–42.
5. Burrows L.J., Basha M., Goldstein A.T. The effects of hormonal contraceptives on female sexuality: A review. J Sex Med, 2012, vol. 9, pp. 2213–2223.
6. Lundin C., Danielsson K.G., Bixo M. et al. Combined oral contraceptive use is associated with both improvement and worsening of mood in the different phases of the treatment cycle-A double-blind, placebo-controlled randomized trial. Psychoneuroendocrinology, 2017, vol. 76, pp. 135–143.
7. Scheuringer A., Lundin C., Derntl B. et al. Use of an estradiol-based combined oral contraceptives has no influence on attentional bias or depressive symptoms in healthy women. Psychoneuroendocrinology, 2020, vol. 113, pp. 104544.
8. Both S., Lew-Starowicz M., Luria M. et al. Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM). J Sex Med, 2019, vol. 16 (11), pp. 1681–1695.
9. Graziottin A. The shorter, the better: A review of the evidence for a shorter contraceptive hormone-free interval. Eur. J. Contracept. Reprod. Heal. Care, 2016, no. 21, rr. 93–105.
10. Nyunt A., Stephen G., Gibbin J.et al. Androgen status in healthy premenopausal women with loss of libido. J. Sex. Marital. Ther, 2005, vol. 31, pp. 73–80.
11. Smith N.K., Jozkowski K.N., Sanders S.A. Hormonal contraception and female pain, orgasm and sexual pleasure. J Sex Med, 2014, vol. 11, pp. 462–470.
12. Warnock J.K., Clayton A., Croft H. et al. Comparison of androgens in women with hypoactive sexual desire disorder: Those on combined oral contraceptives (COCs) vs. those not on COCs. J Sex Med, 2006, vol. 3, pp. 878–882.
13. De Castro Coelho F., Barros C. The Potential of Hormonal Contraception to Influence Female Sexuality. Int J Reprod Med, 2019, p. 9701384.
14. Lete I., de la Viuda E., Perez-Campos E. et al. Effect on quality of life of switching to combined oral contraception based on natural estrogen: an observational, multicentre, prospective phase IV study (ZOCAL Study). Eur. J. Contracept Reprod. Health Care, 2016, vol. 21 (4), pp. 276–284.
15. Cagnacci A., Bastianelli C., Neri M. et al. Treatment continuation and satisfaction in women using combined oral contraception with nomegestrol acetate and oestradiol: a multicentre, prospective cohort study (BOLERO). Eur J Contracept Reprod Health Care, 2018, Dec, vol. 23 (6), pp. 393–399. DOI: 10.1080/13625187.2018.1541080. Epub 2018 Nov 22.
16. Caruso S., Cianci S., Cariola M. et al. Improvement of low sexual desire due to antiandrogenic combined oral contraceptives after switching to an oral contraceptive containing 17β-estradiol. Journal of Women’s Health, 2017, vol. 26 (7), pp. 728–734.